New hope for tough lymphomas: vorinostat shows promise in early trial
NCT ID NCT00875056
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called vorinostat in 56 people with certain types of lymphoma (follicular, other indolent B-cell, or mantle cell) that had returned or stopped responding to prior treatments. The main goal was to see how many patients' tumors shrank or disappeared (response rate) and to check for side effects. The study was completed, and results help understand if vorinostat might be a useful option for these hard-to-treat lymphomas.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can engineered immune cells tackle brain lymphoma?